The FDA issued a statement announcing Medtronic’s decision to voluntarily suspend distribution of its Sprint Fidelis defibrillation leads because a small number of fractures have been detected. As a result of Medtronic’s action, no more Sprint Fidelis leads will be sold or manufactured and any remaining product should be pulled from inventory and returned to the company.

For More information and legal assistance visit these websites:

FDA Question and Answers

Medtronic Device Recall Lawyer

Medtronics Website

Consumer Alerts, Defective Products, Recalls, Top Stories